“Single-cell analysis market projected to register a CAGR of 16.5%”
The single-cell analysis market is expected to reach USD 3.59 billion by 2022 from USD 1.67 billion in 2017, at a CAGR of 16.5%. Technological advancements in single-cell analysis products, increasing government funding for cell-based research, growing biotechnology and biopharmaceutical industries, wide applications of single-cell analysis in cancer research, growing focus on personalized medicine, and increasing incidence and prevalence of chronic and infectious diseases are driving the growth of the single-cell analysis market. On the other hand, the high cost of single-cell analysis instruments may hinder the growth of the market in the coming years.
“Consumables segment are expected to witness high growth during forecast period”
Based on product, the single-cell analysis market is segmented into consumables and instruments. Consumables are expected to register the highest CAGR during the forecast period. Consumables are further segmented into beads, microplates, reagents, assay kits, and other consumables, whereas, instruments are further segmented into flow cytometers, NGS systems, PCR instruments, HCS systems, microscopes, cell counters, spectrophotometers, cell microarrays, and other instruments. Players from the market are increasingly focusing on technological advancements and product development to launch efficient cytometry instruments which is driving the growth of the segment.
“Human cells to dominate the single-cell analysis market”
Based on the type of cells, the single-cell analysis market is segmented into human, animal, and microbial cells. The human cells segment is expected to dominate this market with the largest share in 2017. The large share of this segment can be attributed to the growing application areas of human stem cells and rising incidence of diseases such as cancer.
“NGS to account with the highest growth rate in the single-cell analysis market”
Based on technique, the single-cell analysis market is segmented into flow cytometry, NGS, PCR, microscopy, mass spectrometry, and other techniques (including single-molecule fluorescence in situ hybridization, micromanipulation, and automated capillary electrophoresis). NGS segment is projected to grow at the highest rate during the forecast period.
“North America to dominate the market during forecast period”
In 2017, North America is expected to account for the largest share of the single-cell analysis market. Factors such as increasing collaborations among prominent players, technological advancements and expanding biotechnology and pharmaceutical industries are supporting the growth of the single-cell analysis market in this region. Asian region is expected to register the highest CAGR during the forecast period. The large population in China and India, rising geriatric population, and increasing incidence of chronic diseases are the major factors driving the growth of the Asian market.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 – 35%; Tier 2, 40%; Tier 3, 25%.
- By Designation: C- level- 35%; D-level- 25%; others- 40%.
- By Region: North America – 43%; Europe- 19%; Asia- 29%; and Rest of the World (RoW) - 9%
*Note: Others include sales managers, marketing managers, and product managers
Tiers of the companies are defined by their total revenue. As of 2016: Tier 1 = > USD 1 billion, Tier 2 = USD 100 million to USD 1 billion, and Tier 3 = < USD 100 million
List of Companies Benchmarked in the report
- Merck KGaA (Germany)
- Becton, Dickinson and Company (U.S.)
- Promega Corporation (U.S.)
- Danaher Corporation (U.S.)
- General Electric Company (U.K.)
- Thermo Fisher Scientific Inc. (U.S.)
- Miltenyi Biotec (Germany)
- Illumina, Inc. (U.S.)
- Bio-Rad Laboratories, Inc.(U.S.)
- Fluidigm Corporation (U.S.)
- NanoString Technologies, Inc. (U.S.)
- Agilent Technologies (U.S.)
- Abcam Plc (U.S.)
- NuGEN Technologies Inc.(U.S.)
- LumaCyte (U.S.)
- PluriSelect Life Science UG & Co. KG (Germany)
- Sysmex Partec (U.S.)
- Bio-Techne Corporation (U.S.)
- Promega Corporation (U.S.)
- 10x Genomics (U.S.)
- WaferGen Bio-systems, Inc. (U.S.)
- Bruker (U.S.)
- Fluxion Biosciences (U.S.).
The report provides a picture on global single-cell analysis across various medical devices. It aims at estimating the market size and future growth potential of this market across different segments such as products, cell type, technique, application, end user, and regions. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them the closest approximations of the revenue numbers for the overall single-cell analysis market and the subsegments. This report will help stakeholders to better understand the competitor landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. The report also helps the stakeholders to understand the pulse of the market and provides them information on key market drivers, restraints, challenges, and opportunities.